Lisa Rojkjaer is Chief Medical Officer at Viracta Therapeutics, Inc. (VIRX). They have made 6 open-market trades across 1 company since 2021, most recently 2026-06-01.
CIK 0001846460
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VIRX | SELL | 2023-02-27 | 2023-02-28 | $1.68 | $4K | -2.9% | -12.1% | -21.8% |
| VIRX | SELL | 2022-11-28 | 2022-11-29 | $2.72 | $6K | -24.3% | -44.2% | -26.1% |
| VIRX | SELL | 2022-08-26 | 2022-08-29 | $4.01 | $9K | +29.8% | +7.6% | -37.9% |
| VIRX | SELL | 2022-05-26 | 2022-05-27 | $1.90 | $4K | +50.7% | +51.2% | +98.1% |
| VIRX | SELL | 2022-02-28 | 2022-03-01 | $2.78 | $7K | -12.8% | +68.8% | -24.8% |
| VIRX | SELL | 2021-11-26 | 2021-11-29 | $4.81 | $22K | -5.8% | -24.6% | -38.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.